According to today’s article on Bloomberg Quint, “EU Could Approve BioNTech, Moderna Vaccines in December.”
Shares of Moderna jumped 5.22% to $97.61 at 16:05 EST on Friday. The Nasdaq Stock Market is sliding 0.14% to $11887.9, on what seems, so far, a somewhat rough trend trading session on The Nasdaq Stock Market.
According to yesterday’s article on Bloomberg Quint, “Moderna Vaccine Production Is Gearing Up, Partner Lonza Says.”
Moderna’s last close was $92.77, below its 52-week high of $103.2.
Moderna’s sales growth is 1216.8% for the current quarter and 2299% for the next. The company’s growth estimates for the present quarter is a negative 67.6% and positive 142.9% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s stock is valued at $97.61 at 16:05 EST, below its 52-week high of $103.2 and way above its 52-week low of $17.68.
Moderna’s worth is way higher than its 50-day moving average of $75.37 and way above its 200-day moving average of $68.93.
According to Bloomberg Quint on Tue Nov 17, “Moderna Vaccine Offers Possible Antidote to Deep-Freeze Problem.”